BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical & Diagnostic

CanSinoBIO’s iPneucia® Vaccine Targets Deadly Pneumococcal Threat in Chinese Children with Precision and Safety

Pneumonia is a form of acute respiratory infection, that is common in all age groups and can cause mild to life-threatening illness. It is also the single ...

June 23, 2025 | News

Harbour BioMed and Otsuka Ink $670M+ Global Deal to Advance Bispecific T-Cell Engager for Autoimmune Diseases

Harbour BioMed, a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology,&nb...

June 23, 2025 | News

XtalPi and DoveTree Sign $100M+ LOI to Accelerate AI-Driven Drug Discovery Across Oncology and Neurology

XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, announced it has signed a Letter of Intent (LOI) with DoveTre...

June 23, 2025 | News

Immuno Cure and PharmaJet Partner on Needle-Free HIV Therapeutic Vaccine Study in Hong Kong

Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased to announce its upcoming collaboratio...

June 20, 2025 | News

Pierre Fabre Acquires Global Rights to Next-Generation EGFR Inhibitors for Lung Cancer

Pierre Fabre Laboratories are pleased to announce the acquisition from Antares Therapeutics, Inc. ("Antares"), a spin-out of Scorpion Therapeutics, Inc., o...

June 17, 2025 | News

BioDlink Secures NAFDAC Approval for Bevacizumab Injection, Marking Strategic Entry into the African Market

BioDlink's Bevacizumab Injection has been granted marketing authorization by Nigeria's National Agency for Food and Drug Administration an...

June 17, 2025 | News

Debiopharm and Alkyon Therapeutics Join Forces to Advance Precision Radioligand Cancer Therapies

Research program combining Debiopharm’s AbYlink™ conjugation technology with Alkyon’s modular antibody platform and novel targeting app...

June 16, 2025 | News

Abbisko Therapeutics’ Pimicotinib NDA Accepted by China NMPA for Tenosynovial Giant Cell Tumor

Abbisko Therapeutics Co., Ltd. announced that the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) f...

June 11, 2025 | News

Sanyou Biopharmaceuticals and Medicovestor Forge Strategic Partnership to Advance First-in-Class Chemoimmunotherapy ADCs

Sanyou Biopharmaceuticals, a leading Shanghai-based high-tech biopharmaceutical company specializing in biologics R&D announced the signing ...

June 11, 2025 | News

Harrow Secures Exclusive U.S. Rights to BYQLOVI for Post-Surgical Eye Care Following FDA Approval

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today a...

June 10, 2025 | News

VivaVision Receives Positive FDA Feedback on VVN461LD Phase 2 Trial for Ocular Inflammation

VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, announced today t...

June 10, 2025 | News

Echosens and Boehringer Ingelheim Expand Partnership to Address the Growing Burden of MASH

As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure—affecting...

June 10, 2025 | News

YolTech Therapeutics Receives FDA IND Clearance for In Vivo Base Editing Therapy YOLT-101

YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, announced that the U.S. Food and Drug ...

June 09, 2025 | News

GenEditBio Doses First Patient in World's First In Vivo CRISPR Trial for TGFBI Corneal Dystrophy

GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions through the discovery o...

June 09, 2025 | News

Stay Connected